Different Exercise Modalities in Chronic Kidney Disease: A Longitudinal Intervention Study
NCT07932184, Not applicable, Not yet recruiting, China Institute of Sport Science
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Different Exercise Modalities in Chronic Kidney Disease: A Longitudinal Intervention Study | ClinicalTrials.gov |
| NCT number | NCT07932184 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | China Institute of Sport Science | ClinicalTrials.gov |
| Conditions | Chronic Kidney Disease (CKD), Renal Dysfunction | ClinicalTrials.gov |
| Interventions | Aerobic Exercise, resistance training, Combined Exercise | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Estimated glomerular filtration rate | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Estimated glomerular filtration rate will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Primary | Renal resistance index | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | The renal resistance index (RI) will be assessed by qualified physicians using Doppler ultrasonography of the bilateral interlobar arteries. Measurements will be obtained at standardized sampling sites in both kidneys, with a sampling gate of 2-4 mm and a Doppler angle of less than 60°. | ClinicalTrials.gov |
| Primary | Serum creatinine | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Serum creatinine will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Primary | The four standard blood lipid parameters | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | The four standard blood lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), will be measured using blood samples collected from participants. | ClinicalTrials.gov |
| Primary | blood glucose | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | blood glucose will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Primary | Urinary protein | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Urinary protein levels will be measured using urine samples collected from participants. | ClinicalTrials.gov |
| Primary | Urinary albumin-to-creatinine ratio | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | The urinary albumin-to-creatinine ratiowill be measured using urine samples collected from the participants. | ClinicalTrials.gov |
| Primary | Endogenous Creatinine Clearance | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Endogenous creatinine clearance will be measured using urine samples collected from the participants. | ClinicalTrials.gov |
| Secondary | 6-minute walk test | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Participants will walk as far as possible at their maximum tolerable pace within 6 minutes, and the total distance walked will be recorded. | ClinicalTrials.gov |
| Secondary | 30-second sit-to-stand test | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Participants will complete as many sit-to-stand repetitions as possible within 30 seconds, and the total number of completed repetitions will be recorded. | ClinicalTrials.gov |
| Secondary | vital capacity | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Vital capacity will be measured using a standardized spirometer. | ClinicalTrials.gov |
| Secondary | grip strength | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Handgrip strength will be assessed using a calibrated handgrip dynamometer | ClinicalTrials.gov |
| Secondary | Body fat percentage | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Body fat percentage will be measured using an InBody body composition analyzer. | ClinicalTrials.gov |
| Secondary | malondialdehyde | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Malondialdehyde will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Secondary | superoxide dismutase | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Superoxide dismutase will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Secondary | glutathione peroxidase | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Glutathione peroxidase will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Secondary | C-reactive protein | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | C-reactive protein will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Secondary | interleukin-6 | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | interleukin-6 will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Secondary | tumor necrosis factor-α | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Tumor necrosis factor-α will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
| Secondary | Interleukin-10 | Baseline and at 2, 4, 6, and 12 months after initiation of the intervention | Interleukin-10 will be measured using blood samples collected from the participants. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)